Mucocutaneous Findings in Behçet’s Disease

Arzu Kilic

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/67841

Abstract

Behçet’s disease is a chronic inflammatory disease with an unpredictable course. The disease may affect almost all organ systems resulting with significant organ-threatening morbidity and mortality. Mucocutaneous lesions mostly constitute the initial symptoms of the disease and precede other manifestations. As there is yet no pathognomonic diagnostic test in Behçet’s disease, the recognition of cutaneous and mucosal findings let the physician enable an earlier diagnosis and earlier treatment. Therefore, the purpose of this chapter is to emphasize the importance of the mucocutaneous manifestations of Behçet’s disease and to review the mucocutaneous lesions in detail. Finally, childhood Behçet’s disease, differential diagnosis and treatment of mucocutaneous manifestations will be briefly reviewed.

Keywords: Behçet’s disease, mucocutaneous manifestations, oral ulcer, genital ulcer, papulopustular lesions, pathergy test

1. Introduction

Behçet’s disease (BD) is a chronic, relapsing inflammatory multi-systemic disease of unknown etiology with a course of exacerbations and remissions [1–4]. Prevalence of BD is higher in countries lying along the ancient Silk Road, extending from eastern Mediterranean to East Asia [5]. Turkey probably has the highest occurrence level of the disease with prevalences of 110–420 cases per 100,000 population [6–8]. Today, due to immigrations, BD is encountered almost all over the world [9, 10].

The disease was first defined in 1937 by the Turkish dermatologist named as ‘Hulusi Behçet’ with the presence of ‘triple symptom complex’ of recurrent oral ulcers (OU), genital ulcers
(GU) and uveitis [1]. After the initial description, it now became increasingly evident that BD is a multi-systemic disease with involvement of mucocutaneous, vascular, neurological, musculoskeletal and gastrointestinal systems with significant morbidity and mortality [2, 3, 9, 11, 12]. The main histopathological finding is the vasculitis of the arteries and veins of any size or thrombophilia according to the site of involvement [13].

Although the exact etiopathogenesis of BD is still unknown, it has been hypothesized that in genetically predisposed individuals, a development of an inflammatory reaction against to an infectious, an environmental or an autoantigen and/or the presence of disturbances in molecular mechanisms in regulating immune responses may contribute to the disease [2, 3, 11, 14–17].

Today, most of the authors classify BD as a group of systemic vasculitis (under the title of variable vessel vasculitis) as a result of the consensus; ‘2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides’ [18].

The first symptoms of BD usually occur in the third and fourth decade of life [2, 4, 9, 19]. However, childhood cases have also been reported [20]. Juvenile BD was found in 7.7% and family history was found in 11.6% of the patients in the study reported by Alpsoy et al. [21]. In another study by Gurler et al., the presence of family history in the first degree relatives of patients with BD has been reported as 7.3% [22]. Male patients, a younger onset and HLA-B51 positive patients are found to have more severe kind of the disease [11, 21, 23, 24]. Contrary to these results, Davatchi et al. found no association between severe organ involvement and male gender except vascular involvement [25]. Clinical features of BD include OU, GU, ocular inflammation, cutaneous lesions, as well as articular, vascular, neurological, pulmonary, gastrointestinal, renal and genitourinary manifestations [2–4, 11]. BD may start with just one or two symptoms but other symptoms may gradually appear over the years [19, 22, 24, 26–29].

As there is no pathognomonic test, the diagnosis of BD depends on clinical criteria [3]. In 1990, the International Study Group (ISG) for BD defined new diagnostic criteria by reviewing the data of 914 patients from 12 centres in seven countries around the world. The ISG criteria for BD have a sensitivity of 92% and specificity of 97%, compared with previous sets of criteria. According to these criteria, the diagnosis of BD consists of the presence of recurrent OU in addition to two of the following features: GU, eye involvement, skin lesions and positive skin pathergy test. At minimum three episodes of oral aphthous ulcer in a year should be observed for the diagnosis of BD [30]. In order to increase the sensitivity and specificity, these criteria are re-assessed and revised [31]. Since patients may present with only OU for a long time showing a long prediagnostic duration [19, 22, 32].

Various studies from different countries have documented that mucocutaneous manifestations are the most common, and often the first signs of the disease [2, 3, 9, 11, 21, 22, 24, 26–29, 33–37]. Mucocutaneous findings are the hallmarks of the disease and recognition of them have a great importance in confirming the diagnosis, in the follow up and in preventing both the morbidity and mortality [2, 3, 19, 21, 26, 28].
This chapter aims not only to define the mucocutaneous lesions but also to elaborate the features of the mucosal and cutaneous lesions in detail. Furthermore, mucocutaneous lesions in paediatric BD, differential diagnoses and the management of the mucocutaneous lesions will briefly be reviewed.

2. Mucocutaneous manifestations

Mucocutaneous manifestations that are observed in the course of BD are as follows: OU, GU, erythema nodosum (EN)-like lesions, papulopustular (PPL) lesions, superficial thrombophlebitis (TFB), extragenital ulcers, Sweet’s syndrome-like lesions, cutaneous vasculitic lesions, pyoderma gangrenosum (PG)-like lesions, erythema multiforme-like lesions and skin pathergy test (SPT) [2–4, 9, 32].

The above-mentioned mucocutaneous lesions may be the initial findings of BD or may be observed at any time during the course of the disease [21, 22, 24, 28, 29]. Especially, OU is the most commonly detected lesion and mostly emerges as the initial clinical finding of the disease [2, 3, 19, 21, 33–37]. OU and GU are mostly considered as the ‘fingerprint lesions’. As there is yet no pathognomonic test for the diagnosis of BD, recognition of these mucocutaneous lesions let the clinician make an earlier diagnosis, which also enables an earlier treatment [2, 3].

2.1. Oral ulcers

Oral ulcers (OUs) manifest in the majority of BD patients with a ratio of 92–100% in all countries [2–4, 6, 10, 21, 22, 27, 28, 33]. The majority of the patients experience OU as the most common presenting clinical manifestation [21, 22, 24, 26, 28, 34, 37]. For the diagnosis of BD, the presence of recurrent OU is obligatory according to criteria of ISG [4, 30].

OUs are recurrent and painful ulcerations of the oral mucosa characterized by a round or oval ulceration with sharp borders surrounded by a red erythematous inflammatory area (Figure 1). The base of the OU is necrotic with a yellowish-white colour. The most common sites are the mucous membranes of the lips, buccal mucosae, tongue, uvula and soft palate [2, 3, 22]. Clinically, they look like similar in appearance with conventional aphthae that may be seen in several systemic diseases such as inflammatory bowel disease, Sweet syndrome, systemic lupus erythematosus or recurrent aphthous stomatitis (RAS) [2, 12, 32]. OU in BD tends to recur more frequently and to be more in number [38]. Main and Chamberlain reported that OUs in BD have a more diffuse erythematous surrounding rim, they are localized more often in soft palate and oropharynx and they are more in number when compared with the aphthae of RAS [39]. However, no difference was found in terms of frequency of OU between the two groups [39].

OUs are usually classified into three groups based on the diameter of the ulcer [2, 11]:

1. Minor aphthae are shallow mucosal ulcers with a diameter less than 10 mm. It usually spontaneously regresses in a couple of weeks without formation of scarring.
2. Major aphthae have a deeper morphology with a diameter larger than 10 mm. Healing usually occurs in 3–4 weeks with scarring.

3. Herpetiform aphthae are pinpoint shaped, very small and shallow mucosal ulcers and localized in crops.

The majority of the patients were found to have minor aphthous ulcer (75%) followed by herpetiform (20%) and major aphthae (5%) in the study of Vaiopoulos et al. [36]. Different sizes and types of OU may be seen at the same time in oral mucosa in BD [9]. A study comparing the characteristics of OU between BD and RAS was performed by Oh et al. They reported that major OUs were significantly more common in patients with BD, and initiation of OU in BD was more likely related to menstrual cycle when compared with OU in patients with RAS. In addition, they also concluded that patients with major aphthae who have accompanying articular symptoms as initial symptoms should be strictly followed for the possible development of BD [40].

Ideguchi et al. evaluated 412 BD patients’ data including 16 years follow-up. The results revealed that a mean of 7.5 years has been proceeded before a definitive diagnosis of BD. In the same study, 14% of the patients had suffered from OU for more than 20 years before the diagnosis of BD [19].

In two different studies reported by Alpsoy et al., the mean duration between the OU and the fulfilment of diagnostic criteria was determined to be 4.3 ± 5.7 and 3.77 ± 4.43 years, respectively.
and it has been concluded that the disease is often diagnosed with a delay of several years after the appearance of the first sign [21, 26].

Although OUs are the most common and earliest manifestation of BD, a few studies have been reported indicating a course without the presence of OU at the onset of BD [27, 41–44]. On the basis of this issue, Faezi et al. evaluated the clinical features on 175 patients with BD who do not have oral aphthosis (NOA) and compared them with the patients with OU. The results revealed that the first manifestation was uveitis with a ratio of 70.3% in the NOA group, and a pathergy test was more common in NOA group [41].

2.2. Genital ulcers

Genital ulcers (GUs) are generally the second most frequent disease manifestation [2, 9, 21, 26, 28, 45, 46]. GUs are observed in approximately 60–97% of the patients with BD at any time of the course of the disease [4, 19, 21, 22, 28, 36, 43, 47]. The lowest frequency was reported from Romania with a ratio of 55.5% [43]. As an initial symptom, GU was found in 14.2 and 7.4% of the patients with BD in two different studies from Turkey [21, 22] while in only 4% of the patients with BD in a study from Moscow [34].

GUs are usually localized on the scrotum and on the shaft of the penis in male patients while on the labium major and minor in females (Figures 2 and 3). They are rarely seen in the vagina and cervix in females and on the urethral orifice and glans penis in males [2, 3, 9, 11, 22]. They are usually painful or very rarely they can be asymptomatic [2]. They have mostly the same characteristic morphological features of OU. The clinical differences from oral aphthous ulcer include that GUs are larger and deeper, have more irregular borders and a longer healing duration. In addition, GU recurs less often and heal with scarring [3, 32, 48]. Therefore, in the suspicion of diagnosis of BD, scatris of GU on genital region should also be searched.

While some studies have documented higher frequency of GU among one of the genders [21, 24, 35], some did not detect any difference between the two genders [23, 25, 34]. Gender differences (Male>female) at the onset of GU have been observed in the study by Vaiopoulos et al. [36].

GU may cause severe pain, difficulty in micturition, dyspareunia and marked difficulty in physical activity. Deep ulcers located in vagina may be complicated by fistulisation to bladder, urethra or rectum [2–4, 9].

Mat et al. reported a prospective study investigating the frequency of scarring after GU. This study revealed that healing with scarring was observed in 49% of small GU while in 89% of large ulcers. They stated that ulcers on labium minors and vestibule may heal even without scar formation [48].

Faezi et al. reported 64.7% of 6935 cases with BD had GU during the course of the disease. They compared clinical and laboratory features between the patients with GU and patients who never developed GU (non-GU cases). As a result of their study, OU and other cutaneous manifestations such as pseudofolliculitis and erythema nodosum were found to be higher while eye involvement was found to be less common in the GU group [46].
Figure 2. Genital, extragenital ulcers and their scars in male patient with Behçet’s Disease (Courtesy of MD. Assoc. Prof. Müzeyyen Gönül).

Figure 3. Genital ulcer in female patient with Behçet’s Disease (Courtesy of MD. Assoc. Prof. Müzeyyen Gönül).
2.3. Cutaneous lesions

2.3.1. Papulopustular lesions

Papulopustular lesions (PPLs), which are also called as pseudofolliculitis or Behcet’s pustulosis, are dome-shaped papules, which will convert into sterile pustule with an erythematous and edematous base [2–4]. Sometimes it can be localized around a hair follicle [9]. They are commonly seen lesions in BD [2–4]. Various studies have reported an incidence ranging between 25 and 55% [21, 22, 28, 33, 36]. PPLs have also been reported as an onset sign [22].

PPLs are usually localized on the trunk, buttocks and extremities [2, 3, 49]. However, they may be observed on any part of the body and even on palmoplantar regions [9]. In case of face and chest localization, especially in adolescence period, it may be hard to distinguish PPL from an ordinary papul/pustule of acne or folliculitis [2].

PPLs were found to occur more frequently in male patients than females in a study by Tursen et al. [35]. PPLs were found to occur more in patients with positive pathergy test [49].

Since PPLs are non-specific and resemble to ordinary acne pustules and/or folliculitis; some authors suggest that non-follicular lesions located other than face are more valuable for the diagnosis of BD [2, 27, 49] while some suggest that PPL should not be included as a diagnostic criteria [50]. It is suggested to accept PPL as a diagnostic criteria only if leukocytoclastic vasculitis or a neutrophilic reaction histopathologically is detected [2, 50].

A study by Kalkan et al. reported the histopathological evaluation of 42 biopsy specimens of papulopustular lesions of patients with BD. The results revealed leukocytoclastic vasculitis in seven specimens, lymphocytic vasculitis in three, superficial perivascular and/or interstitial infiltration in 15 and folliculitis/perifolliculitis in five. No histopathological finding of vasculitis was observed in the biopsy specimens of pustular lesions of the patients with acne vulgaris in the control group [51].

Another study by Ilknur et al. reported a statistically higher ratio of lymphocytic/leukocytoclastic vasculitis pattern in the histopathological evaluation of pustular lesions of the patients with BD compared with the control group. However, direct immunofluorescence examinations investigating the deposition of IgM, IgG, IgA, C3 or fibrinogen in dermal blood vessels revealed no difference between the two groups [52].

Chen et al. reported either lymphocytic or leukocytoclastic vasculitis of the 20 biopsy specimens performed from cutaneous lesions of BD. Eight of the 20 biopsy specimens in which vasculitis detected histopathologically was clinically compatible with PPL [53].

Contrary to these studies, Kutlubay et al. compared the number and histopathological features of PPL between patients with BD and acne vulgaris, as a result, Kutlubay et al. assessed a higher number of PPL on the back and extremities in BD group. However, histopathological interpretation was not found to be useful in differentiating PPL between two entities [54].
2.3.2. Erythema nodosum-like lesions

Erythema nodosum (EN)-like lesions are frequently observed skin lesions in patients with BD [9]. The incidences of EN-like lesions have been reported between 15 and 60% in various studies [21, 22, 24, 28, 55, 56]. In 2.8% of the patients with BD, EN-like lesions have been reported as an initial symptom [22]. They are more common in female patients [23, 24, 36, 55]. They are characterized by multiple painful subcutaneous nodules with different sizes. Although they are preferentially located on the lower limbs, they may also be localized on gluteal region, upper extremities and neck [2, 3, 9, 22, 55]. They heal within 10–20 days without secondary ulceration and scatris formation. The resolution generally results with residual hyperpigmentation [2]. The clinical features of EN-like lesions resemble conventional EN [2, 3, 9, 11]. However, it has been noted that EN-like lesions have more erythema and oedema around the lesions than the classical EN [57]. Coskun et al. reported that the presence of EN-like lesions precede visceral involvement [55]. Faezi et al. found less common EN-like lesions among the group of BD without OA in their study in which they compared the two groups with OA and without OA [41]. Cebeci et al. compared the clinical features of two groups with and without deep vein thrombosis (DVT) in BD and found more common EN-like lesions in the group with DVT suggesting that patients with EN-like lesions should be followed up for a possible DVT [58].

The evaluation of the histopathological features of biopsy specimens performed from EN-like lesions has been reported in various studies [57, 59, 60]. Chun et al. detected focal lymphocytic vasculitis in 40% of the cases with EN-like lesions of patients with BD and suggested this finding to occur secondary to severe lymphocytic infiltration. On the rest of the cases, the histopathological changes have been found similar to conventional EN [59]. In contrary, two different studies revealed the presence of vasculitis in biopsy specimens performed from EN-like lesions of patients with BD [57, 60].

Misago evaluated the clinicopathological features of EN-like lesions in 26 patients with BD and revealed the presence of vasculitis histopathologically in 73% of the cases. In addition, they suggested that the presence of severe vasculitis, especially phlebitis, was associated with a severe disease course [57].

A study by Demirkesen et al. compared the distinguishing histopathological features of the biopsy specimens taken from EN-like lesions of BD, nodular lesions of nodular vasculitis (NV) and conventional EN. Their results revealed neutrophil-predominating infiltrate in the sub-cutis and vein involvement to be more common in EN-like lesions when compared with NV and EN [60].

2.3.3. Superficial thrombophlebitis

BD may affect all types of vessels [3, 11, 61]. The prevalence of vascular involvement in BD has been reported to be between 2.2 and 50% in different patient populations [4, 6, 43, 62–64]. The venous system is the major affected site [9, 11, 61–65]. Superficial thrombophlebitis (TFB) is seen in approximately 4.9–20% of the patients with BD, and it is more frequently seen in
male patients [6, 28, 29]. Sarica-Kucukoglu et al. reported superficial TFB as the most common vascular symptom with a prevalence of 53.3% [62].

Superficial TFB is mostly characterized by linearly arranged erythematous subcutaneous nodules in lower extremities that migrate from day to day. The vein can be palpated as a string-like hardening showing the thrombosis and vessel sclerosis [2, 3]. EN-like lesions and migratory TFB may be thought as the differential diagnosis [2, 3]. Superficial TFB is clinically important since it is frequently associated with other forms of vascular disease in BD [2, 63].

2.3.4. Extragenital ulcers

Extragenital ulcer (EGU) is usually a solitary, small, round ulcer with a red rim and yellow base; however, it may have various shapes and sizes [2, 3, 32, 65]. Although observed rarely, it is the most characteristic and specific lesions of BD [2, 65]. EGU may be localized anywhere on the body such as legs, axillae, breast, interdigital skin of the foot, neck and inguinal regions. EGU may persist for a long duration, may be painful and heals usually with scarring [2, 3]. In a report of Azizlerli et al., four cases of EGU were shown to reveal vasculitis histopathologically [65].

A study reported by Ozyurt et al. detected that the patients with family history of BD had more frequent EGU than patients with negative family history of BD [66].

Few series documented common EGU in children [67, 68]. However, due to rarity of BD in childhood and few reports concerning the clinical findings in children with BD, the characteristics of the disease in this age group are not completely described [67–69].

2.3.5. Sweet’s syndrome-like lesions

Few cases of Sweet’s syndrome-like lesions have been reported in patients with BD [70–77]. Sweet’s syndrome-like lesions are characterized by painful, edematous papules, plaques and nodules localized on face, neck and back [3, 70–75]. Fever and laboratory findings such as leukocytosis, elevated erythrocyte sedimentation rate and C-reactive protein accompany to the cutaneous lesions [73, 74]. Although clinical and histological overlap exists between Sweet’s syndrome and BD such as the presence of OU, arthralgia, arthritis, episcleritis, pathergy positivity and neutrophilic infiltrate in the dermis in both of the diseases, there are some distinguishing features. In BD, the development of OU is more frequent, fever is rarely seen, the pattern of articular and ocular involvement is different [3]. In addition, comparing two diseases by human leucocyte antigen (HLA) typing revealed that patients with BD had higher frequencies of HLA-B51 and HLA-Dqw3, while patients with Sweet’s syndrome had higher frequencies of HLA-Bw4 [77]. Sweet’s syndrome-like lesions have been reported to occur in the acute phase of BD or sometimes have been thought to point a flare in BD [73].

2.3.6. Pyoderma gangrenosum-like lesions

Pyoderma gangrenosum (PG) is another rare neutrophilic dermatosis that may be associated with BD [78, 79]. Rare cases of PG-like lesions in patients with BD have been addressed
The lesion is usually characterized by large superficial ulceration localized usually on the buttock or the lower limbs; however, it may reveal vegetative or bullous variants [9, 79, 81]. Both diseases may have clinical and histopathological overlap. The patients with PG may also have OU, GU and pathergy positivity [78, 79]. However, as mentioned above, the frequency of OU and GU is higher in BD. It has been reported that PG is associated with the activation of BD [78, 79, 85]. Also, Hali et al. reported two paediatric cases of BD and PG with a fatal outcome [84].

2.3.7. Rare cutaneous lesions

Other rare cutaneous lesions such as palpable purpura, haemorrhagic bullae, necrotizing vasculitic lesions, Henoch Schoenlein purpura, polyarteritis nodosa-like lesions, pernio-like lesions, erythema multiforme-like lesions, acral purpuric papulonodular lesions, furuncles and abscess may also occur in the course of BD [2, 3, 70, 86–97]. It has been suggested that lesions of periarteritis nodosa appear as a marker of the severity of BD [91, 92]. These cutaneous lesions are mostly presented as case reports [86–97]. It is not clear whether these dermatological manifestations are real associations or coincidental. Therefore, it has been postulated that only lesions of ‘leukocytoclastic vasculitis’ detected in histopathological examination should be evaluated as a cutaneous sign of BD [2, 53, 98, 99].

2.3.8. Rare mucosal lesions

Conjunctival ulceration has been reported as a manifestation of BD in a few reports [100–104]. Although it is a rare finding, it has been suggested to be a specific clue for establishing the diagnosis [102, 103].

2.4. Skin pathergy test

Skin pathergy test (SPT) is a non-specific hyperreactive reaction of the skin that occurs as a response to a minor trauma such as a needle prick [2, 3]. SPT was first described by Blobner in 1937 [70, 105]. It is used as an adjunctive test in the diagnosis of BD and according to the ISG criteria for BD, a positive SPT is a criteria needed for the diagnosis of BD [2, 3, 30, 70, 105].

Positive SPT is defined as the development of erythematous, indurated papule which usually evolves into a sterile pustule at the site of the needle puncture after 24–48 hours (Figure 4) [70, 105]. Although the exact mechanism of the SPT is still not known, it is thought to occur as a result of enhanced non-specific inflammatory response and aberrant release of cytokines triggered by the cutaneous injury [13]. A number of studies investigating the histopathological examinations of positive SPT reaction (papule/pustule) revealed findings ranging from mononuclear cell infiltration at varying densities in perivascular or periadnexal areas to leukocytoclastic vasculitis [106–110]. Ergun et al. evaluated a chronological histopathological study of sites of SPT and observed intraepidermal pustules and polymorphonuclear infiltrate at the beginning of the inflammation [108]. Androjen receptor levels were found higher in positive SPT sites when compared with normal skin [111].
Although the positivity of SPT has been accepted as a criteria in the diagnosis of BD, there is no consensus about performing a standardized method of SPT [105, 112–117]. It is usually performed under sterile conditions with a 20-gauge needle inserted intradermally into the avascular area on the forearm skin of patient with an angle of 45° [105, 112, 113]. Various techniques such as pricking with multiple needles with various applying routes including intradermal, intravenous and subcutaneous methods have been reported [9, 105, 112, 114–116]. Multiple punctures are mostly required [9, 114, 115]. Davatchi et al. suggested three intradermal punctures perpendicular or diagonally one with a 25-gauge needle with intradermal injection of one drop of normal serum saline, one with a 25-gauge needle alone (just a puncture, with no injection) and the last with a 21 gauge needle (puncture, no injection) [115]. A study by Ozdemir et al. suggested that two needle pricks are sufficient for positive SPT [114]. Another study by Ozdemir et al. analysed the changes of SPT positivity in different body areas such as flexor surfaces of the forearms, the lateral aspect of the tibial area, the scapular areas on back, and the lumbar areas of the abdominal region. They concluded that forearm was the most frequent site positive for pathergy reaction whereas abdomen was the least [113]. Akmaez et al. reported higher rate of positivity in SPT by intradermal application compared with intravenous application [117]. Dilsen et al. performed SPT with different needles including sharp and blunt needles in which they confirmed higher frequency of positivity with blunt needles [112]. Sharquie et al. demonstrated an alternative method of which they inserted the needle inside the mucous membrane of the lower lip to the sub-mucosa. However, the sensitivity of the oral pathergy test has been reported lower than of the classical pathergy test [118].

Various prevalence rates of SPT positivity in BD have been reported by several studies [21, 22, 119–123]. The positivity of SPT varies between 40 and 88% with a higher prevalence in Japan and Mediterranean countries, whereas it is lower in countries such as the United Kingdom and the United States [2, 3, 9, 22, 45, 98, 119–123]. Alpsoy et al. reported the positivity of SPT as 37.8% in their study including 661 Turkish patients with BD [21]. A study

Figure 4. Pathergy positivity in Behçet’s Disease (Courtesy of MD. Assoc. Prof. Müzeyyen Gönül).

Mucocutaneous Findings in Behçet’s Disease
http://dx.doi.org/10.5772/67841
Comparing the positivity of SPT between Turkish and British patients with BD revealed the positive reaction was only present among Turkish patients [119]. In a German study, SPT revealed positive results in 33.7% of patients with no significant difference between Turkish and German patients with BD [123]. The factors that may affect the rates of positivity of SPT include genetic variables, variations in ethnic origins of the patients, factors related to the method and materials used to perform the SPT and conditions of the patient and the disease [105, 112–114, 124–126].

Contrary results have been reported about the relationship between positive SPT and clinical course of BD [22, 125–128]. Chang et al. found that positive SPT was specific for BD, but not associated with clinical severity [125]. Similarly, Krause et al. found no difference in terms of clinical manifestations and severity in the comparison of pathergy positive and negative patients with BD [126]. Although Yazici et al. have found no correlation between disease severity and positive SPT, they reported that male patients with BD have stronger pathergy reaction [127]. Jorizzo et al. reported a correlation between the histopathological pathergy results and clinical severity [109]. Koç et al. detected higher positive SPT test in patients with vascular involvement compared to patients without vascular involvement [128].

It has been reported that the frequency of SPT positivity has decreased during the last years [115, 125, 129]. One of the best reasons for this issue is the use of disposable needles, which are less traumatic than non-disposable ones [105, 112, 125]. A study by Davatchi et al. investigated the sensitivity and specificity of SPT among 6607 patients followed between the years 1975 and 2010. Their results revealed that the sensitivity of pathergy test has declined, but it still preserves its specificity [115]. Moreover, positivity of SPT in many diseases other than BD has been detected. Neutrophilic dermatoses such as Sweet syndrome, PG, erythema elevatum or other diseases such as RAS, eosinophilic pustular folliculitis, inflammatory bowel diseases and spondyloarthropathies are some in which pathergy reaction positivity has been shown [70]. Despite everything, SPT has still a diagnostic value [115].

3. Childhood Behçet’s disease and mucocutaneous manifestations

BD in childhood is rare, has a variable clinical course and less investigated [68, 69, 130–139]. Paediatric onset of BD was found in 5.3 and 7.6% of all the cases [130, 133]. In the study including 661 cases of BD, juvenile BD has been reported in 7.1% [21]. In paediatric cases, a family history of BD has been more frequently observed [21, 68, 130, 131, 136, 137].

The diagnosis of paediatric BD in the reported studies was based on the criteria of ISG and ICD [30, 31]. A recent classification was proposed by Kone-Paut et al., and according to this classification, the presence of any three items among recurrent oral aphthosis, GU, ocular involvement, neurological and vascular signs makes the definitive diagnosis of BD [135, 140].
The onset of BD has been reported at any age between 0 and 16 years [131, 136, 137]. The lowest mean age of 4.8 years old was reported by Nanthapisal et al. [134]. Similarly to clinical symptoms of adulthood BD, OU was present in most of the children and also constituted the initial symptom in most of the cases [68, 131–139]. The localization and morphology of OU in children were also similar to the characteristics of adulthood OU [136, 137, 140]. GU was detected between 55 and 94% of the paediatric cases [131, 135–138]. Distinctively from adult cases, the presence of GU has been reported significantly lesser than adults [131, 132]. However, Treudler et al. did not reveal any differences in the ratio of GU between childhood and adulthood BD [68], and Nanthapisal et al. detected recurrent GU more frequently in females [134]. The characteristics of GU were also found similar to the ones seen in adults [136, 137]. Another distinctive feature, perianal aphthosis was to be a specific feature of childhood BD [135].

Skin lesions were reported to occur between 64 and 92% of childhood BD [70, 135, 137, 138]. Kone-Paut et al. reported EN-like lesions in 40% and necrotic folliculitis in 58% [136], while Borlu et al. reported EN-like lesions in 18% and PPL in 47% of the patients [137]. Kone-Paut et al. reported necrotic folliculitis more frequently in male patients [136]. However, no gender differences were detected in terms of skin lesions in the study of Borlu et al. [137]. Erythema multiforme-like lesions and TFB have been less frequently reported [70]. Positive SPT has been reported in 37, 80 and 76% of the patients in three different studies [131, 136, 137].

Nanthapisal et al. documented skin findings in 11 (23.9%) of 46 patients: These were pustular lesions in three, skin ulceration in two, EN in two, necrotic folliculitis in two, PPL in two and positive SPT in three of the five patients [134].

The duration between the initial symptom and fulfillment of diagnosis of BD has been reported as 3.14 years in the study of Karincaoglu et al. [131], while a significant diagnostic delay up to 13.5 years has been reported in the study of Nanthapisal et al. [134]. This may be caused due to rarity and unfamiliarity of the disease in Northern Europe.

Conflicting reports have also been found in the systemic expression of BD in children [130, 132, 133]. BD was usually reported to have a less severe disease [132, 140]. Pivetti-Pezzi et al. reported similar rates of OU, GU, skin lesions in the comparison of adulthood and childhood BD. In addition, no differences were observed in the incidence of arthritis, gastrointestinal and neurological involvement except more severe ocular involvement in childhood. Another study by Sarica et al. compared the patients with mild and severe diseases. An earlier onset and more systemic involvement were found in patients with severe form of the disease [130]. More frequent neurological and gastrointestinal involvements were observed in childhood BD in the study of Karincaoglu et al. [131].

Generally, it can be interpreted that juvenile BD has a similar clinical spectrum to adulthood BD. The differences in frequency and clinical courses may reflect the geographic, ethnic and genetic variations.
4. Differential diagnosis of mucocutaneous manifestations

The differential diagnosis of mucocutaneous manifestations will not be addressed in detail as this subject does not constitute the main topic of this chapter. Only the essential differential diagnoses of OU, GU, EN-like lesions will be given below.

**Oral ulcer** [2, 32, 141]:

- Infectious etiology: Herpangina, primary herpetic gingivostomatitis, hand-foot and mouth disease, HIV, syphilis, tuberculosis, etc.
- Systemic diseases: Systemic lupus erythematos, Reiter’s disease, Wegener’s granulomatosis, blood disorders (neutropenia, leukaemia), iron deficiency, vitamin B12 deficiency, etc.
- Gastrointestinal diseases: Inflammatory bowel diseases, Celiac Disease
- Primary skin conditions: Sweet’s syndrome, RAS, autoimmune bullous disorders (pemphigus vulgaris, pemphigoid, linear IgA disease, etc.)
- Medication induced: Cytotoxic agents, nicorandil, etc.
- Malign neoplasms

**Genital ulcer** [2, 32, 142, 143]:

- Infectious etiology: Genital herpes simplex, syphilis, chancre, lymphogranuloma venereum, granuloma inguinale, HIV, etc.
- Non-microbial etiology: Erythema multiforme, fixed drug eruption, Lipschütz ulcers, metastatic Crohn’s disease, hidradenitis suppurativa, PG, pressure ulcers, sexual trauma, psoriasis and malignancies.

**Papulopustular lesions** [2, 54, 144, 145]:

- Infectious etiology: Gram-positive folliculitis, Gram-negative folliculitis, Pityrosporum folliculitis, Demodicidosis, viral plane warts
- Eosinophilic pustular folliculitis
- Acne vulgaris

**Erythema nodosum-like lesions** [2, 70]:

- Classical EN
- Nodular vasculitis
- Panniculitis
- Cellulitis

**Extragenital ulcers** [146]:
5. Treatment of mucocutaneous manifestations

Oral and genital ulcers can be treated with topical and systemic treatments [3, 147–152]. In recurrent OU with or without GU, systemic colchicine (1–2 mg/day) must be started as a first choice of treatment [147–149]. Topical steroids, topical sucralfate, local anaesthetics, and tetracycline oral mouth washes are usually combined with oral colchicine treatment [147]. In case of more severe and painful OU and/or GU, a short duration of systemic steroids may be added with colchicine. Corticosteroids combined with systemic antibiotics can be used to decrease the severity of GU attacks [147–149]. In patients with severe mucocutaneous manifestations, immunosuppressive drugs such as azathioprine (AZA), methotrexate (Mtx), cyclosporine A may be used [149]. AZA has been found effective in preventing the recurrences of thrombophlebitis [147]. Thalidomide is another choice of therapy in recalcitrant OU and/or GU. However, it is not preferred due its high toxic effects [147, 149, 150]. Pentoxifylline, dapsone, zinc sulphate, IFN-α and rebamipide are other alternative treatments worth for trying in OU. However, larger and well organized studies are needed in order to clarify their efficacies. In case of EN-like lesions, bed rest is usually required. Especially in female cases with GU and EN-like lesions, the combination of colchicine and benzathine penicillin is recommended [148]. This treatment combination has also been reported to decrease the frequency and duration of both OU and EN-like lesions [150]. IFN-α has been reported to decrease not only the frequency of GU and EN-like lesions but also the number of PPL [151]. Anti-TNF drugs are being used with success in patients with refractory mucocutaneous manifestations [151, 152]. Recent studies of interleukin-1 (IL-1) inhibitors (anakinra, canakinumab) have demonstrated efficacy in OU and GU resistant to conventional therapy [150]. Finally, apremilast, phosphodiesterase 4 inhibitor, has been reported to be effective in treating OU and GU [150, 152]. The treatment options can be seen more detailed in Table 1.
Mucocutaneous lesions are the most important criteria in establishing the diagnosis of BD. In case of recurrent OU, GU and other cutaneous findings mentioned above, it is important to remind the possibility of BD in the diagnosis, which will permit an earlier diagnosis and enable a decrease in mortality and morbidity.

### Table 1. Treatment options for mucocutaneous manifestations.

| Mucocutaneous manifestation | Topical | Systemic |
|-----------------------------|---------|----------|
| Oral ulcer                  | Topical steroids, Topical sucralfate, Local anaesthetics, Topical amlexanox, Local silver nitrate 5% | Colchicine, Tetracycline, Azithromycin, Systemic steroids (short term), Rebamipide, Dapson, Immunosuppressive drugs (AZA, Mtx), Thalidomide, Anti-TNF drugs, IFN-α, Pentoxifylline, Cyclosporine A (Cyc A), Tacrolimus, Apremilast, Anakinra, Canakinumab |
| Genital ulcer               | Topical antibiotics, Topical steroids, Local anaesthetics | Colchicine, Tetracycline, AZA, Mtx, CycA, IFN-α, Anti-TNF, Apremilast, Anakinra, Canakinumab |
| Papulopustular lesion       | Bed rest, Wet dressings (aluminium acetate 3–5%) | Colchicine, Azithromycin, CycA, IFN-α, Thalidomide |
| Erythema nodosum-like lesions | Bed rest, Wet dressings (aluminium acetate 3–5%) | Colchicine, NSAI, Systemic steroids (short term), Colchicine+benzathine penicillin, Dapson, Anti-TNF |

### 6. Conclusion

Mucocutaneous lesions are the most important criteria in establishing the diagnosis of BD. In case of recurrent OU, GU and other cutaneous findings mentioned above, it is important to remind the possibility of BD in the diagnosis, which will permit an earlier diagnosis and enable a decrease in mortality and morbidity.
Abbreviations

AZA Azathioprine
BD Behçet’s disease
DVT Deep vein thromboses
EGU Extragenital ulcer
EN Erythema nodosum
GU Genital ulcers
HLA Human leucocyte antigen
IFN-α Interferon-alpha
ISG International study group
Mtx Methotrexate
NV Nodular vasculitis
PG Pyoderma gangrenosum
PPL Papulopustular lesions
RAS Recurrent aphthous stomatitis
SPT Skin pahergy test
TFB Thrombophlebitis
OU Oral ulcer

Author details

Arzu Kilic
Address all correspondence to: kilicarzu@gmail.com
Department of Dermatology, Balikesir University School of Medicine, Balikesir, Turkey

References

[1] Behçet H. Über rezidivierende, aphthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochensch. 1937;36:1152–7.

[2] Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous Lesions of Behçet’s disease. Yonsei Med J. 2007;48: 573–85. DOI: 10.3349/ymj.2007.48.4.573
[3] Alpsoy E. Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43:620–32. DOI: 10.1111/1346-8138.13381

[4] Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13:57–65. DOI: 10.1080/1744666X.2016.1205486

[5] Verity DH, MarrJE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the Silk Road and HLA-B51: historical and geographic perspectives. Tissue Antigens 1999;54:213–20.

[6] Azizlerli G(1), Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, Tunç R, Urgancioğlu M, Dişçi R. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803–6.

[7] Yurdakul S, Günaydın I, Tüzün Y. The prevalence of Behçet’s syndrome in a rural area in Northern Turkey. J Rheumatol. 1988;15: 820–2.

[8] Idil A, Gurler A, Boyvat A, et al. The prevalence of Behcet’s disease above the age of ten years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol. 2002;9:325–31.

[9] Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi Abdollahi B. Behçet’s disease: from East to West. Clin Rheumatol. 2010;29:823–33. DOI: 10.1007/s10067-010-1430-6.

[10] Mohammad A(1), Mandl T, Sturfelt G, Segelmark M. Incidence, prevalence and clinical characteristics of Behçet’s disease in southern Sweden. Rheumatology (Oxford). 2013;52:304–10. DOI: 10.1093/rheumatology/kes249.

[11] Dalvi SR, Yildirim R, Yazici Y. Behçet’s Syndrome. Drugs.2012;72:2223–41. DOI: 10.2165/11641370-000000000-00000.

[12] Yazici Y, Yurdakul S, Yazici H. Behçet’s syndrome. Curr Rheumatol Rep. 2010;12:429–35. DOI: 10.1007/s11926-010-0132-z.

[13] Melikoglu M, Kural-Seyahi E, Tascilar K, Yazici H. The unique features of vasculitis in Behçet’s syndrome. Clin Rev Allergy Immunol. 2008;35:40–6. DOI: 10.1007/s12016-007-8064-8.

[14] Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E. Relationship between periodontal findings and Behcet’s disease: a controled study. J Clin Periodontol. 2007;34:485–91. DOI: 10.1111/j.1600-051X.2007.01085.x

[15] Gül A. Pathogenesis of Behçet’s disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37: 413–8. DOI: 10.1007/s00281-015-0502-8.

[16] Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4: 81–3.
[17] Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int. 2007;27: 417–24. DOI: 10.1007/s00296-006-0281-6

[18] Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guilllevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. DOI: 10.1002/art.37715.

[19] Ideguchi H, Suda A, Takeno M, Ueda A. Behçet disease: evolution of clinical manifestations. Medicine. 2011;90: 125–32. DOI: 10.1097/MD.0b013e318211bf28

[20] Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutuktun I, Assaad-Khalil S, Hofer M, Kummerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA; PED-BD International Expert Committee. Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011; 50:184–8. DOI: 10.1093/rheumatology/keq324

[21] Alpsoy E(I), Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157:901–6. DOI: 10.1111/j.1365-2133.2007.08116.x

[22] Gurler A, Bovyat A, Tursen U. Clinical Manifestations of Behçet’s disease: an analysis of 2147 patients. Yonsei Med J. 1997;38: 423–7. DOI: 10.3349/ymj.1997.38.6.423

[23] Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozayzagan Y, Ozdoğan H, Serdaroglu S, Ersanli M, Ulkü BY, Müftüoğlu AU. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984; 43:783–9.

[24] Balta I, Akbay G, Kalkan G, Eksioglu M. Demographic and clinical features of 521 Turkish patients with Behçet’s disease. Int J Dermatol. 2014; 53: 564–9. DOI: 10.1111/j.1365-4632.2012.05756.x

[25] Davatchi F, Shahram F, Chams-Davatchi C, Sadeghi Abdollahi B, Shams H, Nadji A, Faezi T, Akhlaghi M, Ghodsi Z, Larimi R, Ashoefteh F. Behcet’s disease: is there a gender influence on clinical manifestations? Int J Rheum Dis. 2012;15: 306–14. DOI: 10.1111/j.1756-185X.2011.01696.x.

[26] Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B. Review of the chronology of clinical manifestations in 60 patients with Behçet’s disease. Dermatology. 2003;207:354–6. DOI: 74113
[27] Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, Bajocchi G, Olivier I, Boiardi L. Epidemiology and Clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 2007;57:171–8. DOI: 10.1002/art.22500

[28] Davatchi F, Chams-Davatchi C, Shams H, Nadji A, Faeezi T, Akhlaghi M, Sadeghi Abdollahi B, Ashofteh F, Ghodsi Z, Mohtasham N, Shahram F. Adult Behçet's disease in Iran: analysis of 6075 patients. Int J Rheum Dis. 2016; 19: 95–103. DOI: 10.1111/1756-185X.12691

[29] Yucel A, Marakli SS, Aksungur VL, et al. Clinical evaluation of Behçet's disease: a five year follow-up study. J Dermatol. 2005;32: 365–70.

[30] International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335:1078–80.

[31] International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28: 338–47. DOI: 10.1111/jdv.12107

[32] Gunduz O. Histopathological evaluation of Behçet’s disease and identification of new skin lesions. Patholog Res Int. 2012;2012:209316. DOI: 10.1155/2012/209316.

[33] Zhang Z(1), He F, Shi Y. Behçet’s disease seen in China: analysis of 334 cases. Rheumatol Int. 2013;33: 645–8. DOI: 10.1007/s00296-012-2384-6.

[34] Lennikov A, Alekberova Z, Goloeva R, Kitaichi N, Denisov L, Namba K, Takeno M, Ishigatsubo Y, Mizuki N, Nasonov E, Ishida S, Ohno S. Single center study on ethnic and clinical features of Behçet’s disease in Moscow, Russia. Clin Rheumatol. 2015; 34:321–7. DOI: 10.1007/s10067-013-2442-9.

[35] Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol. 2003; 42:346–51.

[36] Vaiopoulos G, Konstantopoulos P, Evangelatos N, Kaklamakis PH. The spectrum of mucocutaneous manifestations in Adamantiades-Behçet’s disease in Greece. J Eur Acad Dermatol Venereol. 2010; 24: 434–8. DOI: 10.1111/j.1468-3083.2009.03435.x.

[37] Rodríguez-Carballeira M, Alba MA, Solans-Laqué R, Castillo MJ, Ríos-Fernández R, Larrañaga JR, Martínez-Berriotxoa A, Espinosa G; REGEB investigators. Registry of the Spanish network of Behçet’s disease: a descriptive analysis of 496 patients. Clin Exp Rheumatol. 2014;32:S33–9.

[38] Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, Weinberger A. Recurrent apthous stomatitis in Behçet’s disease. Clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med. 1999; 28:193–6.

[39] Main DM, Chamberlain MA. Clinical differentiation of oral ulceration in Behçet’s disease. Br J Rheumatol. 1992; 31:767–70.
[40] Oh SH, Han EC, Lee JH, Bang D. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clin Exp Dermatol. 2009;34:e208–12. DOI: 10.1111/j.1365-2230.2009.03384.x

[41] Faezi ST, Paragomi P, Shahram F, Shams H, Shams-Davatchi C, Ghodsi Z, Nadji A, Akhlaghi M, Davatchi F. Clinical features of Behçet's disease in patients without oral aphthosis. Mod Rheumatol. 2014; 24: 637–9. DOI: 10.3109/14397595.2013.844400.

[42] Bang D, Lee JH, Lee ES, Lee S, Choi JS, Kim YK, Cho BK, Koh JK, Won YH, Kim NI, Park SD, Ahn HJ, Lee YW, Wang HY, Lee WW, Eun HC, Song ES, Lee CW, Lee CJ, Park JH, Song YW, Kim ST, Kim CY, Park JK, Kwon KS. Epidemiologic and clinical survey of Behçet’s disease in Korea: the first multicenter study. J Korean Med Sci. 2001;16: 615–8.

[43] Tanasenau St, Pompilian V, Cojocaru I, et al. Clinical particularities in a Romanian series of Behçet’s disease patients. Clin Exp Rheumatol. 2004;22:Suppl S84.

[44] Dilsen N. The implications of nonaphthous beginning of Behçet’s disease. Adv Exp Med Biol. 2003;528: 73–6.

[45] Davari P, Rogers RS, Chan B, Nagler TH, Fazel N. Clinical features of Behçet’s disease: A retrospective chart review of 26 patients. J Dermatolog Treat. 2016; 27:70–4. doi: 10.3109/09546634.2015.1054781

[46] Faezi ST, Chams-Davatchi C, Ghodsi SZ, Shahram F, Nadji A, Akhlaghi M, Moradi K, Paragomi P, Ghazizadeh Esslami G, Sadeghi Abdollahi B, Ashofteh F, Davatchi F. Genital aphthosis in Behçet’s disease: is it associated with less eye involvement? Rheumatol Int. 2014;34:1581–7. DOI: 10.1007/s00296-014-3011-5.

[47] al-Dalaan AN, al Balaa SR, el Ramahi K, et al. Behçet’s disease in Saudi Arabia. J Rheumatol 1994;21: 658–61.

[48] Mat Cem. The frequency of scarring after genital ulcers in Behçet’s syndrome: a prospective study. Int J Dermatol. 2006;45: 554–6. DOI:10.1111/j.1365-4632.2006.02859.x

[49] Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E. A randomized, controlled and blinded study of papulopustular lesions in Turkish Behçet’s patients. Int J Dermatol. 1998;37: 839–4.

[50] Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, Gaffney K, Mat C, Yazici H, al Ialaan A, et al. Mucocutaneous findings for the diagnosis of Behçet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol. 1995;32:968–76.

[51] Kalkan G, Karadag AS, Astarci HM, Akbay G, Ustun H, Eksioglu M. A histopathological approach: when papulopustular lesions should be in the diagnostic criteria of Behçet’s disease? J Eur Acad Dermatol Venereol. 2009 Sep;23:1056–60. DOI:10.1111/j.1468-3083.2009.03256.x.
[52] Ilknur T, Pabuççuoglu U, Akin C, Lebe B, Gunes AT. Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behçet’s disease. Eur J Dermatol. 2006;16:146–50.

[53] Chen KR, Kawahara Y, Miyakawa S, Nishikawa T. Cutaneous vasculitis in Behçet’s disease: a clinical and histopathologic study of 20 patients. J Am Acad Dermatol. 1997;36:689–96.

[54] Kutlubay Z, Mat CM, Aydin Ö, Demirkesen C, Calay Ö, Engin B, Tüzün Y, Yazıcı H. Histopathological and clinical evaluation of papulopustular lesions in Behçet’s disease. Clin Exp Rheumatol. 2015;33:S101–6.

[55] Coskun B, Ozturk P, Saral Y. Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet’s disease. Int J Clin Pract. 2005; 59:69–71. DOI: 10.1111/j.1742-1241.2005.00286.x

[56] Ajose OA, Adelowo O, Oderinlo O. Clinical presentations of Behçet’s disease among Nigerians: a 4-year prospective study. Int J Dermatol. 2015; 54:889–97. DOI: 10.1111/ijd.12554

[57] Misago N, Tada Y, Koarada S, Narisawa Y. Erythema nodosum-like lesions in Behçet’s disease: a clinicopathological study of 26 cases. Acta Derm Venereol. 2012; 92:681–6. DOI: 10.2340/00015555-1349

[58] Cebeci F, Onsun N, Ulusal HA, Inan B. The relationship between deep vein thrombosis and erythema nodosum in male patients with Behçet’s disease. Eur Rev Med Pharmacol Sci. 2014; 18:3145–8.

[59] Chun SI, Su WP, Lee S, Rogers RS 3rd. Erythema nodosum-like lesions in Behçet’s syndrome: a histopathological study of 30 cases. J Cutan Pathol. 1989; 16:259–65.

[60] Demirkesen C, Tuzuner N, Mat C, Senocak M, Buyukbabani N, Tuzun Y, Yazıcı H. Clinicopathological evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol. 2001;116:341–6. DOI: 10.1309/GCTH-0060-55K8-XCTT

[61] Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Sadeghi Abdollahi B. How to deal with Behçet’s disease in daily practice. Int J Rheum Dis. 2010; 13: 105–16.

[62] Sarica-Kucukoglu R, Akdag-Kose A, Kayaball M, Yazganoglu KD, Disci R, Erzengin D, Azizlerli G. Vascular involvement in Behçet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45:919–21. DOI: 10.1111/j.1365-4632.2006.02832.x

[63] Düzgün N, Ateş A, Aydintuğ OT, Demir O, Olmez U. Characteristics of vascular involvement in Behçet’s disease. Scand J Rheumatol. 2006; 35:65–8. DOI: 10.1080/03009740500255761

[64] Hamdan A, Mansour W, Uthman I, Masri AF, Nasr F, Arayssi T. Behçet’s disease in Lebanon: clinical profile, severity and two-decade comparison. Clin Rheumatol. 2006;25:364–7. DOI: 10.1007/s10067-005-0058-4
[65] Azizlerli G, Ozarmağan G, Ovül C, Sarica R, Mustafa SO. A new kind of skin lesion in Behçet’s disease: extragenital ulcerations. Acta Derm Venereol. 1992;72:286.

[66] Ozyurt K, Colgecen E, Baykan H. Does familial occurrence or family history of recurrent oral ulcers influence clinical characteristics of Behçet’s disease? Acta Dermatovenerol Croat. 2013;21:168–73.

[67] Krüger K, Fritz K, Daniel V, Zouboulis CC. Juvenile Adamantiades-Behçet disease in decreased stimulation with anti-CD3 monoclonal antibody. [Article in German] Hautarzt. 1997; 48:258–61.

[68] Treudler R, Orfanos CE, Zouboulis CC. Twenty-eight cases of juvenile-onset Adamantiades-Behçet disease in Germany. Dermatology. 1999; 199: 15–9. DOI: 18197

[69] de Carvalho VO, Abagge KT, Giraldi S, Kamoi TO, Assahide MK, Fillus Neto J, Marinoni LP. Behçet disease in a child—emphasis on cutaneous manifestations. Pediatr Dermatol. 2007;24:E57–62. DOI: 10.1111/j.1525-1470.2007.00442.x

[70] Lee ES, Bang D, Lee S. Dermatologic manifestation of Behçet’s disease. Yonsei Med J. 1997;38: 380–9. DOI: 10.3349/ymj.1997.38.6.380

[71] Oguz O, Serdaroglu S, Tuzun Y, Erdogan N, Yazici H, Savaskan H. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) associated with Behçet’s disease. Int J Dermatol. 1992; 31:645–6.

[72] Cho KH, Shin KS, Sohn SJ, Choi SJ, Lee YS. Behçet’s disease with Sweet’s syndrome-like presentation—a report of six cases. Clin Exp Dermatol. 1989;14: 20–4.

[73] Wu F, Luo X, Yuan G. Sweet’s syndrome representing a flare of Behçet’s disease. Clin Exp Rheumatol. 2009;27:588–90.

[74] Lee MS, Barnetson RS. Sweet’s syndrome associated with Behçet’s disease. Australas J Dermatol. 1996;37: 99–101.

[75] Uysal H, Vahaboğlu H, Inan L, Vahaboğlu G. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) in neuro-Behçet’s disease. Clin Neurol Neurosurg. 1993;95:319–22.

[76] Karadoğan SK, Başkan EB, Alkan G, Sarıcaoğlu H, Tunali S. Generalized Sweet syndrome lesions associated with Behçet disease: a true association or simply co-morbidity? Am J Clin Dermatol. 2009;10:331–5. DOI: 10.2165/11310790-000000000-00000.

[77] Mizoguchi M, Matsuki K, Mochizuki M, Watanabe R, Ogawa K, Harada S, Hino H, Amagai M, Juji T. Human leukocyte antigen in Sweet’s syndrome and its relationship to Behçet’s disease. Arch Dermatol. 1988;124:1069–73.

[78] Ozuguz P, Kacar SD, Manav V, Karaca S, Aktepe F, Ulu S. Genital ulcerative pyoderma gangrenosum in Behçet’s Disease: a case report and review of the literature. Indian J Dermatol. 2015;60:105. DOI: 10.4103/0019-5154.147866.

[79] Kim JW, Park JH, Lee D, Hwang SW, Park SW. Vegetative pyoderma gangrenosum in Behçet’s disease. Acta Derm Venereol. 2007;87:365–7. DOI: 10.2340/00015555-0221
[80] Chams-Davatchi C, Shizarpour M, Davatchi F, Shahram F, Chams H, Nadji A, Jamshidi AR. Extensive pyoderma gangrenosum-like lesion in two cases of Behçet’s disease responding only to cyclosporin. Adv Exp Med Biol. 2003;528:337–8.

[81] Singh G, Sethi A, Okade R, Harish MR. Bullous pyoderma gangrenosum: a presentation of childhood Behçet’s disease. Int J Dermatol. 2005;44:257–8.

[82] Joshi A, Mamta. Behçet’s syndrome with pyoderma-gangrenosum-like lesions treated successfully with dapsone monotherapy. J Dermatol. 2004;31: 806–10.

[83] Rustin MH, Gilkes JJ, Robinson TW. Pyoderma gangrenosum associated with Behçet’s disease: treatment with thalidomide. J Am Acad Dermatol. 1990;23:941–4.

[84] Hali F, Khadir K, Chiheb S, Bouayad K, Mikou N, Benchikhi H. [Pyoderma gangrenosum and Behçet’s disease: a study of two pediatric cases]. [Article in French]. Arch Pediatr. 2011;18:1320–3. DOI: 10.1016/j.archped.2011.09.007.

[85] Nakamura T, Yagi H, Kurachi K, Suzuki S, Konno H. Intestinal Behçet’s disease with pyoderma gangrenosum: a case report. World J Gastroenterol. 2006; 12:979–81.

[86] Cantini F, Salvarani C, Niccoli L, Senesi C, Truglia MC, Padula A, Olivieri I. Behçet’s disease with unusual cutaneous lesions. J Rheumatol. 1998;25:2469–72.

[87] Ates A, Karaaslan Y, Aslar Zo. A case of Behçet’s disease associated with necrotizing small vessel vasculitis. Rheumatol Int. 2006; 27:91–3. DOI: 10.1007/s00296-006-0155-y

[88] Cornelis F, Sigal-Nahum M, Gaulier A, Bleichner G, Sigal S. Behçet’s disease with severe cutaneous necrotizing vasculitis: response to plasma exchange--report of a case. J Am Acad Dermatol. 1989;21:576–9.

[89] Lee SH, Chung KY, Lee WS, Lee S. Behçet’s syndrome associated with bullous necrotizing vasculitis. J Am Acad Dermatol. 1989;21:327–30.

[90] Park YW, Park JJ, Lee JB, Lee SS. Development of Henoch-Schönlein purpura in a patient with Behçet’s disease presenting with recurrent deep vein thrombosis. Clin Exp Rheumatol. 2007;25:S96–8.

[91] Vikas A, Atul S, Singh R, Sarbmeet L, Mohan H. Behçet’s disease with relapsing cutaneous polyarteritis-nodosa-like lesions responsive to oral cyclosporine therapy. Dermatol Online J. 2003;9:9.

[92] Serra-Guillén C, Llombart B, Alfaro-Rubio A, Hueso L, Martorell-Calatayud A, Requena C, Nagore E, Botella-Estrada R, Sanmartín O, Guillén C. Behçet’s disease and periarteritis nodosa with cutaneous lesions. [Article in Spanish]. Actas Dermosifiliogr. 2007;98:217–8.

[93] Azuma N, Natsuaki M, Yamanishi K, Kondo N, Iwasaki T, Morimoto M, Nishioka A, Sekiguchi M, Kitano M, Hashimoto N, Matsui K, Sano H. [Cutaneous necrotizing vasculitis in a patient with Behçet’s disease; mimicking polyarteritis nodosa]. [Article in Japanese]. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33:149–53.
Liao YH, Hsiao GH, Hsiao CH. Behçet’s disease with cutaneous changes resembling polyarteritis nodosa. Br J Dermatol. 1999;140:368–9.

Trad S, Saadoun D, Barete S, Frances Piette CJ, Wechsler B. Necrotizing folliculitis in Behcqet’s disease. Rev Med Interne. 2009;30:268–270. DOI: 10.1016/j.revmed.2008.06.007

King R, Crowson AN, Murray E, Magro CM. Acral purpuric papulonodular lesions as a manifestation of Behçet’s disease. Int J Dermatol. 1995;34:190–2.

Jefferson JA, Pollack RB. Behçet’s disease with recurrent erythema multiforme in a 20 year-old African American male. J S C Med Assoc. 2011;107:40–1.

Sula B, Batmaz I, Ucmak D, Yolbas I, Akdeniz S. Demographical and Clinical Characteristics of Behçet’s Disease in Southeastern Turkey. J Clin Med Res. 2014;6:476–81. DOI: 10.14740/jocmr1952w.

Schreiner DT, Jorizzo JL. Behçet’s disease and complex aphthosis. Dermatol Clin. 1987;5:769–78.

Shenoy R. Conjunctival ulcer—mucocutaneous or ocular manifestation of Behçet’s disease? A case report. Eur J Ophthalmol 2002;12:435–6.

Merle H, Donnio A, Richer R, Dubreuil F, Arfi S. Isolated conjunctival ulcerations as the first sign of Behçet’s disease. Eur J Ophthalmol. 2006;16:751–2.

Zamir E, Bodaghi B, Tugal-Tutkun I, See RF, Charlotte F, Wang RC, Wechsler B, LeHoang P, Anteby I, Rao NA. Conjunctival ulcers in Behçet’s disease. Ophthalmology. 2003;110:1137–41. DOI: 10.1016/S0161-6420(03)00265-3

Fabian ID, Vishnevskia-Dai V. Conjunctival ulceration in Behçet disease: a case report. BMJ Case Rep. 2009;2009. pii: bcr08.2008.0616. DOI: 10.1136/bcr.08.2008.0616

Matsuo T, Itami M, Nakagawa H, Nagayama M. The incidence and pathology of conjunctival ulceration in Behçet’s syndrome. Br J Ophthalmol. 2002;86:140–3.

Sequeira FF, Daryani D. The oral and skin pathergy test. Indian J Dermatol Venereol Leprol. 2011;77:526–30. DOI:10.4103/0019-5154.143568.

Jorizzo JL, Solomon AR, Cavallo T. Behçet’s syndrome. Immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up. Arch Pathol Lab Med. 1985;109:747–51.

Gul A, Esin S, Dilsen N, Konicê M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behçet’s disease. Br J Dermatol. 1995;132:901–7.

Ergun T, Gürbüz O, Harvell J, Jorizzo J, White W. The histopathology of pathergy: a chronologic study of skin hyperreactivity in Behçet’s disease. Int J Dermatol. 1998;37:929–33.

Ozluk E, Balta I, Akoguz O, Kalkan G, Astarci M, Akbay G, Eksioglu M. Histopathologic study of pathergy test in Behçet’s Disease. Indian J Dermatol. 2014;59:630. DOI: 10.4103/0019-5154.143568.
[110] Inaloz HS, Evereklioglu C, Unal B, Kirtak N, Eralp Ai Inaloz SS. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcet’s syndrome. J Eur Acad Dermatol Venereol. 2004;18:56–61.

[111] Alpsoy E, Elpek GO, Yilmaz F, Ciftcioglu MA, Akman A, Uzun S, Karakuzu A. Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behçet’s disease. Dermatology. 2005;210:31–5. DOI: 10.1159/000081480

[112] Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A. Comparative study of the skin pathergy test with blunt and sharp needles in Behçet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis. 1993;52:823–5.

[113] Ozdemir M, Balevi S, Deniz F, Mevlitoğlu I. Pathergy reaction in different body areas in Behçet’s disease. Clin Exp Dermatol. 2007;32:85–8. DOI: 10.1111/j.1365-2230.2006.02284.x

[114] Ozdemir M, Bodur S, Engin B, Baysal I. Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol. 2008;47:335–8. DOI: 10.1111/j.1365-4632.2008.03568.x.

[115] Davatchi F, Chams-Davatchi C, Ghodsi Z, Shahram F, Nadjji A, Shams H, Akhlaghi M, Larimi R, Sadeghi-Abdolahi B. Diagnostic value of pathergy test in Behcet’s disease according to the change of incidence over the time. Clin Rheumatol. 2011;30:1151–5. DOI: 10.1007/s10067-011-1694-5

[116] Ozden MG, Bek Y, Aydin F, Senturk N, Canturk T, Turanli AY. Different applications techniques of pathergy testing among dermatologists. J Eur Acad Dermatol Venereol 2010;24:1240–42. DOI: 10.1111/j.1468-3083.2010.03622.x

[117] Akmaz O, Erel A, Gürer MA. Comparison of histopathologic and clinical evaluations of pathergy test in Behçet’s disease. Int J Dermatol. 2000;39:121–5.

[118] Sharquie KE, Al-Araji A, Hatem A. Oral pathergy test in Behçet’s disease. Br J Dermatol. 2002;146:168–9.

[119] Yazici H, Chamberlain MA, Tuzun Y, et al. A comparative study of the pathergy reaction among Turkish and British patients with Behcet’s disease. Ann Rheum Dis. 1984;43: 74–5.

[120] Dogan B, Taskapan O, Harmanyeri Y. Prevalence of pathergy test positivity in Behçet’s disease in Turkey. J Eur Acad Dermatol Venereol. 2003;17:227–9.

[121] Askari A, Al-Aboosi M, Sawalha A. Evaluation of pathergy test in North Jordan. Clin Rheumatol. 2000;19:241–51.

[122] Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ. The pathergy test and Behçet’s syndrome in Britain. Ann Rheum Dis. 1984;43: 70–3.

[123] Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L, Zouboulis CC. Epidemiology and clinical manifestations of Adamantiades-Behcet disease in German-current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges. 2006; 4:49–64. DOI: 10.1111/j.1610-0387.2006.05841.x
[124] Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet’s syndrome. Ann Rheum Dis. 1993;52:619–20.

[125] Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behçet’s disease. J Korean Med Sci. 2002;17:371–4. DOI: 10.3346/jkms.2002.17.3.371

[126] Krause I, Molad Y, Mitrani M, Weinberger A. Pathergy reaction in Behçet’s disease: lack of correlation with mucocutaneous manifestations and systemic disease expression. Clin Exp Rheumatol. 2000;18:71–4.

[127] Yazici H, Tüzün Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H, Müftüoglu A. Male patients with Behçet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol. 1985;3:137–41.

[128] Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S, et al. Vascular involvement in Behçet’s disease. J Rheumatol. 1992;19:402–10.

[129] Varol A, Seifert O, Anderson CD. The skin pathergy test: innately useful? Arch Dermatol Res. 2010;302:155–68. DOI: 10.1007/s00403-009-1008-9. Epub 2009 Dec 12.

[130] Sarica R, Azizlerli G, Köse A, Dişiç R, Övül C, Kural Z. Juvenile Behçet’s disease among 1784 Turkish Behçet’s patients. Int J Dermatol. 1996;35:109–11.

[131] Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, Usta A, Kandi B, Durusoy C, Seyhan M, Utas S, Saricaoglu H, Ozden MG, Uzun S, Tursen U, Cicek D, Donmez L, Alpsoy E. Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58:579–84. DOI: 10.1016/j.jaad.2007.10.452

[132] Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, Weinberger A. Childhood Behçet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38:457–62.

[133] Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, La Cava M, Torella M, Riso D. Behçets disease in children. Jpn J Ophthalmol. 1995;39:309–14.

[134] Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA. Paediatric Behçet’s disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35:2509–16. DOI: 10.1007/s10067-016-3187-z.

[135] Koné-Paut I. Behçet’s disease in children, an overview. Pediatr Rheumatol Online J. 2016;14:10. DOI: 10.1186/s12969-016-0070-z.

[136] Koné-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, Bernard JL. Clinical features of Behçet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132:721–5.

[137] Borlu M, Uğsal U, Ferahbaş A, Evereklioglu C. Clinical features of Behçet’s disease in children. Int J Dermatol. 2006;45:713–6. DOI: 10.1111/j.1365-4632.2006.02754.x

[138] Vaiopoulos AG, Kanakis MA, Kapsimali V, Vaiopoulos G, Kaklananis PG, Zouboulis CC. Juvenile Adamantiades-Behçet Disease. Dermatology. 2016;232:129–36. DOI: 10.1159/000442667
Johnson EF, Hawkins DM, Gifford LK, Smidt AC. Recurrent oral and genital ulcers in an infant: neonatal presentation of pediatric Behçet Disease. Pediatr Dermatol. 2015;32:714–7. DOI: 10.1111/pde.12512.

Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuenen-Deschner J, Agostini H, Federici S, Arnoux A, Piedvache C, Ozen S; PEDBD group. Consensus classification criteria for paediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75:958–64. DOI: 10.1136/annrheumdis-2015-208491.

Scully C, Shotts R. ABC of oral health. Mouth ulcers and other causes of orofacial soreness and pain. BMJ. 2000;321:162–5.

Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. Am Fam Physician. 2012;85:254–62.

Kirshen C, Edwards L(2). Noninfectious genital ulcers. Semin Cutan Med Surg. 2015;34:187–91. DOI: 10.12788/j.sder.2015.0168.

Fujiyama T, Tokura Y. Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis. J Dermatol. 2013;40:419–23. DOI: 10.1111/1346-8138.12125.

Del Rosso JQ, Silverberg N, Zeichner JA. When acne is not acne. Dermatol Clin. 2016;34:225–8. DOI: 10.1016/j.det.2015.12.002.

Morton LM, Phillips TJ. Wound healing and treating wounds: Differential diagnosis and evaluation of chronic wounds. J Am Acad Dermatol. 2016;74:589–605; quiz 605-6. DOI:10.1016/j.jaad.2015.08.068.

Alpsoy E. Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23:532–9.

Alpsoy E, Akman A. Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301:693–702. DOI: 10.1007/s00403-009-0990-2.

Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G. Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol. 2011;30:157–63. DOI: 10.1007/s10067-010-1566-4.

Rotondo C, Lopalco G, Iannone F, Vitale A, Talarico R, Galeazzi M, Lapadula G, Cantarini L. Mucocutaneous involvement in Behçet’s Disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm. 2015;2015:451675. DOI: 10.1155/2015/451675.

Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H. Anti-TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology (Oxford). 2007;46:736–41.

Comarmond C, Wechsler B, Bodaghi B, Cacoub P, Saadoun D. Biotherapies in Behçet’s disease. Autoimmun Rev. 2014;13:762–9. DOI: 10.1016/j.autrev.2014.01.056. Epub 2014 Jan 26.